Institution: Western Securities
Researcher: Yang Huan
Event: Yiling Pharmaceutical (002603) released its annual report in 2023 and quarterly report in 2024, and the company achieved revenue in 2023.Crashbashdownloadpc.1.8 billion yuan (year-on-year-17.67%), net profit 1.352 billion yuan (year-on-year-42.76%), deducting non-return net profit 1.265 billion yuan (year-on-year-45.58%); revenue of the company in the first quarter of 2024 was 2.523 billion yuan (year-on-year-35.89%), return-to-mother net profit 304 million yuan (year-on-year-74.73%), deducted non-return net profit 292 million yuan (year-on-year-75.18%), performance short-term pressure.
Under multi-factor performance pressure, non-respiratory products maintain a good situation. In terms of products, the company's cardio-cerebrovascular / respiratory system in 2023CrashbashdownloadpcThe revenue of his patented products / other products was 47.093305, respectively, with revenue of 4.35cm 1.865 billion yuan, compared with the same period last year. + 12.71%, 51.90%, 13.82%, 71.43%, respectively. Respiratory products are expected to be affected by factors such as a high base and a decline in market demand caused by high social inventory in the same period, and non-respiratory products remain in good shape. In 2023, the company's sales gross profit margin is 57.28% (year-on-6.49pcts) and 2024Q1 sales gross profit margin is 51.48% (year-on-13.48pcts). It is expected that due to the rise in raw materials and the decline in the proportion of high-margin continuous flower products, the sales expense rate / management expense rate / financial expense rate / R & D expense rate in 2023 is 26.21%, 5.74%, 0.26%, 8.27%, respectively. Respectively compared with the same period last year + 0.21pcts/+0.86pcts/+0.1pcts/+0.04pcts, R & D investment continued to increase.
The research and development of traditional Chinese medicine is advancing steadily, and the research pipeline is rich. Tongluo Mingmu capsule for the treatment of diabetic retinopathy was approved to go on the market in 2023; patented traditional Chinese medicine Lianhuaqingke tablet changed from prescription to over-the-counter; "Tongxinluo capsule ischemic stroke, Lianhua Qingwen granule in the treatment of influenza in children, Yangzheng Xiaoji capsule to improve the quality of life of patients with advanced non-small cell lung cancer and Xia Liqi capsule in the treatment of benign prostatic hyperplasia and other evidence-based medicine studies have been successfully revealed. The paper "Research on Myocardial Protective effect of Chinese Tongxinluo in the treatment of Acute Myocardial Infarction" was published in the Journal of American Medical Association (JAMA), influencing factor 120.7.
Give a rating of "overweight". It is estimated that the net profit from 2024 to 2026 will be RMB 15.76, 1.847, 1.170 million, compared with + 16.5%, 17.2%, 17.5%, 0.94, 1.11, 1.30 and 20.0x/17.0x/14.5x, respectively. Taking into account the company's unique collateral disease theory under the guidance of patented new drug research and development and academic marketing promotion model, given a "holding" rating.
Risk hints: policy adjustment risk, R & D innovation risk, cost rising risk.